LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Atvērts

3.56 9.2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.24

Max

3.6

Galvenie mērījumi

By Trading Economics

Ienākumi

1.9M

-68M

Pārdošana

-5.8M

42M

Peļņas marža

-163.26

Darbinieki

570

EBITDA

25M

-41M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+38.46% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

60M

1.1B

Iepriekšējā atvēršanas cena

-5.64

Iepriekšējā slēgšanas cena

3.56

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 13. nov. 21:34 UTC

Peļņas

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

2025. g. 13. nov. 23:45 UTC

Tirgus saruna

Nikkei May Fall After Wall Street's Weakness -- Market Talk

2025. g. 13. nov. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

2025. g. 13. nov. 23:41 UTC

Tirgus saruna

Gold Edges Higher on Possible Dip-Buying -- Market Talk

2025. g. 13. nov. 23:24 UTC

Peļņas

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

2025. g. 13. nov. 23:24 UTC

Peļņas

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

2025. g. 13. nov. 23:23 UTC

Peļņas

JBS NV 3Q EPS 52c >JBS

2025. g. 13. nov. 23:23 UTC

Peļņas

JBS NV 3Q Sales $22.6B >JBS

2025. g. 13. nov. 23:04 UTC

Tirgus saruna

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

2025. g. 13. nov. 22:02 UTC

Peļņas

Nu Holdings 3Q Net $783M >NU

2025. g. 13. nov. 22:01 UTC

Peļņas

Nu Holdings 3Q Rev $4.2B >NU

2025. g. 13. nov. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

2025. g. 13. nov. 21:50 UTC

Peļņas

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

2025. g. 13. nov. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

2025. g. 13. nov. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

2025. g. 13. nov. 21:33 UTC

Tirgus saruna

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

2025. g. 13. nov. 21:33 UTC

Peļņas

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

2025. g. 13. nov. 21:31 UTC

Peļņas

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

2025. g. 13. nov. 21:25 UTC

Peļņas

Figure Tech Solutions 3Q Rev $156.4M >FIGR

2025. g. 13. nov. 21:25 UTC

Peļņas

Figure Tech Solutions 3Q EPS 34c >FIGR

2025. g. 13. nov. 21:23 UTC

Peļņas

Intchains Group 3Q Rev $1.3M >ICG

2025. g. 13. nov. 21:03 UTC

Peļņas

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

2025. g. 13. nov. 21:02 UTC

Peļņas

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

2025. g. 13. nov. 21:01 UTC

Peļņas

Applied Materials 4Q Rev $6.8B >AMAT

2025. g. 13. nov. 21:01 UTC

Peļņas

Applied Materials 4Q Gross Margin 48.0% >AMAT

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

38.46% augšup

Prognoze 12 mēnešiem

Vidējais 4.5 USD  38.46%

Augstākais 5 USD

Zemākais 4 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.02 / 2.115Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

No Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat